## William C Cromwell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1249733/publications.pdf

Version: 2024-02-01

20 papers 3,854 citations

16 h-index 19 g-index

21 all docs

21 docs citations

times ranked

21

4098 citing authors

#	Article	IF	Citations
1	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 375, 998-1006.	6.3	813
2	Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy. Clinics in Laboratory Medicine, 2006, 26, 847-870.	0.7	619
3	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, 133-140.	0.6	483
4	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, $2011, 5, S1$ -S8.	0.6	406
5	LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. Journal of Clinical Lipidology, 2007, 1, 583-592.	0.6	365
6	Measurement issues related to lipoprotein heterogeneity. American Journal of Cardiology, 2002, 90, 22-29.	0.7	269
7	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235
8	Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk. Journal of the American College of Cardiology, 2013, 62, 2178-2184.	1.2	213
9	Low-density lipoprotein particle number and risk for cardiovascular disease. Current Atherosclerosis Reports, 2004, 6, 381-387.	2.0	175
10	Heterogeneity of Low-Density Lipoprotein Particle Number in Patients With Type 2 Diabetes Mellitus and Low-Density Lipoprotein Cholesterol < 100 mg/dl. American Journal of Cardiology, 2006, 98, 1599-1602.	0.7	68
11	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2016, 117, 1921-1927.	0.7	43
12	Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease. Current Cardiology Reports, 2009, 11, 468-475.	1.3	37
13	Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. American Journal of Cardiology, 2001, 87, 232-234.	0.7	30
14	Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S46-S51.	0.6	27
15	Mipomersen preferentially reduces small low-density lipoprotein particle number inÂpatients with hypercholesterolemia. Journal of Clinical Lipidology, 2015, 9, 201-209.	0.6	26
16	Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. American Journal of Cardiology, 2000, 86, 1123-1127.	0.7	22
17	High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?. Journal of Clinical Lipidology, 2007, 1, 57-64.	0.6	10
18	Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. American Journal of Cardiology, 2017, 119, 404-409.	0.7	9

#	Article	IF	CITATIONS
19	Arterial Age as a Function of Coronary Artery Calcium. American Journal of Cardiology, 2009, 103, 1330-1331.	0.7	1
20	Utilization of Lipoprotein Subfractions., 2007,, 321-347.		0